CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
Philadelphia, Pennsylvania, United States and 24 other locations
therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma...
Phase 3
Philadelphia, Pennsylvania, United States and 65 other locations
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Camden, New Jersey, United States of America and 53 other locations
of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States
cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 20 other locations
This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monocl...
Phase 2
Philadelphia, Pennsylvania, United States and 3 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Philadelphia, Pennsylvania, United States and 46 other locations
sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States of America and 9 other locations
This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from sp...
Phase 2
Philadelphia, Pennsylvania, United States
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...
Phase 2
Philadelphia, Pennsylvania, United States and 55 other locations
Clinical trials
Research sites
Resources
Legal